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The EORTC Breast Cancer Group (BCG), created in 1962, is a multidisciplinary
group involving surgeons, medical oncologists, radiation oncologists, pathologists,
basic scientists, and clinical research fellows. Currently, more than 80 member’s
institutions across Europe are participating in the group studies. The main goal of
the BCG is to conduct high-quality international clinical trials covering all areas of
breast cancer care: from loco-regional to systemic disease control, and from in situ
carcinoma to metastatic disease. Over 50 years, the BCG has performed dozens
of clinical studies including several thousands of patients. Many practice-changing
trials and major achievements were conducted optimizing local control, improving
systemic therapy in early and metastatic breast cancer, pioneering work in clinical–
translational trials and collaboration within intergroup trials. The strategic plan of the
BCG for future research includes three distinct albeit overlapping areas: loco-regional
therapy, (neo-)adjuvant systemic therapy, trials in the metastatic setting, and niche
population studies. For each of these areas the group has considered the prevailing
EORTC strategy of focusing on practice-changing studies and translational research,
with an emphasis on niche trials. During ﬁve decades, the BCG has successfully
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performed a series of practice-changing trials enrolling several thousands of patients.
These studies have contributed to the clinical knowledge on the treatment of breast
cancer and have inﬂuenced clinical practice and breast cancer patients’ outcome
worldwide.
© 2012 European Organisation for Research and Treatment of Cancer.
1. Introduction
The European Organization for Research and Treatment
of Cancer (EORTC) Breast Cancer Group (BCG) was created
in 1962 as part of the establishment of the EORTC
by cancer specialists (including surgical, medical, and
radiation oncologists) across Europe with the aim to
perform international clinical research in breast cancer.
The history and activities of the BCG from 1962 to 2002
have been described previously. 1−3
Today, the BCG is a multidisciplinary group involving
surgeons, medical oncologists, radiation oncologists,
pathologists, basic scientists, and clinical research
fellows. The main goal of the BCG is to conduct
high-quality international clinical trials covering all
areas of breast cancer care: from loco-regional to
systemic disease control, and from in situ carcinoma
to metastatic disease. The group actively investigates
new anticancer agents in phase I/II trials, and new
therapeutic strategies in large phase III trials applying
the newest diagnostic modalities, including imaging,
sentinel node assessment, histopathology and molecular
biology. During the last decade translational research
with incorporation of tissue banking has become a top
priority of BCG.
Every two years, the BCG organizes the ‘European
Breast Cancer Conference’ (EBCC) in collaboration with
the European Society of Breast Cancer Specialists
(EUSOMA) and Europa Donna, the European Breast
Cancer Coalition. The eighth EBCC will be held in Vienna
in March 2012 continuing the tradition of previous
conferences by providing excellent opportunities for
dialogue between clinicians, researchers, nurses, and
patient advocates. The aim of these meetings is to create
a platform for closer cooperation between the parties in
order both to stimulate scientiﬁc progress and to provide
better standards of care for breast cancer in Europe and
beyond.
2. Summary of BCG achievements during the ﬁrst
40 years, 1962−2002A
Between 1962 and 1973, the activities of the BCG
were mostly focused on endocrine therapy in advanced
disease. The group was the ﬁrst to demonstrate the
antineoplastic activity of an anti-estrogen, nafoxidine,
which was found to be as effective as ethinyloestradiol in
postmenopausal women. Nafoxidine was later replaced
by a less toxic analogue, tamoxifen. By 1974, a
combination of tamoxifen and two alternating regimens
of chemotherapy, AV (doxorubicin plus vincristine) and
CMF (cyclophosphamide, methotrexate and ﬂuorouracil)
were tested by the group. 4 The achievement of high
response and complete remission rates stimulated
the group to pursue investigations in the ﬁeld of
combined and sequential endocrine therapy and chemo-
therapy.
In the 1980’s, the BCG performed one of the largest
studies (EORTC 10801) comparing mastectomy with
breast-conserving therapy (BCT) in operable breast
cancer, showing that while mastectomy provided slightly
better local control, it did not translate into survival
advantage. 5,6 This and other practice-changing studies
initiated in the 1980−90’s continued to accrue long-term
follow-up data and resulted in several publications in the
last decades of the 20th century, as described below.
In locally advanced disease, the EORTC 10972 trial
demonstrated that either endocrine treatment or chemo-
therapy in addition to radiotherapy signiﬁcantly delayed
the time to ﬁrst progression, with the greatest effect
being achieved with the combination of both (given
concomitantly). For overall survival (OS), endocrine treat-
ment and combination of both showed an improvement,
whereas chemotherapy did not. 7,8 Between 1986 and
1991, 2795 patients were included in EORTC trial 10854
that showed improved local control with peri-operative
chemotherapy, particularly in young women managed
with BCT. 9
Finally, in metastatic disease, the BCG demonstrated
that ‘classical’ CMF is superior to a 3-weekly intravenous
CMF schedule in postmenopausal patients (EORTC
10808). 10 In the EORTC 10881 study, the combination of
tamoxifen and a luteinizing hormone-releasing hormone
(LHRH) inhibitor was found to be superior to either treat-
ment alone in premenopausal patients with advanced
breast cancer. 11 Another study (EORTC 10923) compared
the efﬁcacy of paclitaxel and doxorubicin given as single
agents in ﬁrst-line therapy of advanced breast cancer
with a planned cross-over applied systematically on
progression during ﬁrst-line treatment. This trial demon-
strated that doxorubicin provides better disease control
(objective response and progression-free survival [PFS])
and symptom control (particularly pain) than paclitaxel
A A detailed description has been published previously. 1−3
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as ﬁrst-line treatment. No signiﬁcant survival difference
was observed between the two treatment groups. This
trial additionally identiﬁed non cross-resistance between
doxorubicin and paclitaxel irrespective of what sequence
these drugs are administered. 12
3. Major achievements in the last decade
Over the last three years the BCG has recruited a total of
over 4000 patients from 57 medical centers into clinical
trials, an average of 1340 patients per year.These patients
have been included not only in EORTC studies but also
in intergroup trials in which the EORTC is one of the
partners. High-quality data are ensured by standardized
procedures and fully dedicated personnel including
highly qualiﬁed statisticians at EORTC Headquarters. In
the last few years, most BCG trials have incorporated
a central pathology review process of collected tumor
samples to assure high-quality and annotated pathology
data, which renders possible important translational
research activities. As part of quality assurance activities
in radiotherapy, a survey among EORTC-radiotherapy
centers described precise details of radiotherapy tech-
niques currently implemented for breast irradiation in
Europe and showed that recent advances in radiotherapy
technology are being widely adopted. 13 It indicates that
new radiotherapy techniques, when being addressed in
clinical trials, are feasible within the network of EORTC-
ROG centers.
4. Optimizing local control
4.1. Breast-conserving surgery followed by radiotherapy (RT)
has equivalent long-term efﬁcacy to mastectomy
In the 1980’s, some studies showed that BCT, if followed
by RT, was as effective as mastectomy in the treatment
of breast tumors of 2 cm or smaller. However, evidence
of its long-term efﬁcacy, in patients with tumors larger
than 2 cm, was at that time limited. The EORTC 10801
study, run between 1980 and 1986, was one of the largest
randomized trials (n=868) to compare BCT followed by
RT with modiﬁed radical mastectomy for patients with
operable breast cancer up to 5 cm. Eighty percent of
the patients had a tumor of 2.1−5 cm and 40% positive
lymph nodes. At a median follow-up of 13 years, patients
assigned to BCT had a higher risk of loco-regional
recurrence (HR=1.64, 95%CI: 1.12–2.38; P=0.01) than the
mastectomy group, however there was no difference in
OS (HR=1.13, 95%CI: 0.92–1.39; P=0.246). 14 An update
analysis with 22 years follow-up has been conducted and
will be available soon.
4.2. Addition of boost radiation after BCT improves local
control
In collaboration with the EORTC Radiotherapy Group
the EORTC 22881–10882 trial recruited more than 5000
patients with stage I/II breast cancer treated with BCT
and whole breast irradiation. The study demonstrated
that an additional boost dose of radiation to the tumor
bed reduces the risk of local recurrence (7.3% versus 4.3%;
HR=0.59; P<0.001), particularly in patients below than 50
years of age. 15 The later analysis, with a median follow-
up of 10.8 years, demonstrated that a boost dose of 16Gy
improved local control in all age groups (10-year local
recurrence of 10.2% vs. 6.2%; HR=0.59; P<0.0001 in favor
of boost), but without a difference in OS. 16
4.3. Adjuvant radiotherapy improves local control of DCIS
after BCT
In one of the largest clinical studies ever performed in
ductal carcinoma in situ (DCIS) of the breast, the EORTC
10853 trial, the beneﬁcial effect of RT was demonstrated
in reducing the overall number of both invasive and non-
invasive recurrences in the ipsilateral breast after BCT. 17
With long-term follow-up of ten years, local recurrence-
free rate in the groups treated with local excision with
and without RT was 85% and 74%, respectively (HR=0.53;
P<0.0001). RT after local excision for DCIS continued to
reduce the risk of local recurrence (DCIS and invasive
disease), with a 47% reduction at ten years. All patient
subgroups beneﬁted from RT. 18 A further analysis on a
longer follow-up is planned in the near future.
The BCG also demonstrated in a prospective study
(EORTC 10873) that BCT is a feasible alternative for
patients with Paget disease, a rare type of breast cancer,
and a limited extent of underlying DCIS. To achieve
good local control, treatment should include a complete
excision of the nipple areolar complex including the
underlying disease, followed by irradiation to the whole
breast. 19
5. Improved systemic therapy in early and
metastatic breast cancer
5.1. Neoadjuvant and adjuvant treatment are equivalent in
terms of breast cancer outcome
The hypothesis that preoperative systemic treatment
might be more effective than classical adjuvant treat-
ment was investigated in a phase III trial (EORTC 10902).
This study conﬁrmed that both strategies yield similar
results in terms of PFS, OS, and locoregional control. 20 In
the same setting, another phase III study (EORTC 10921)
showed no beneﬁt of intensiﬁed induction chemotherapy
with granulocyte colony stimulating factor (GCSF) sup-
port, compared with standard chemotherapy. 21
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5.2. Standard anthracycline-based chemotherapy remains a
reasonable treatment choice as ﬁrst-line chemotherapy for
metastatic breast cancer patients not previously treated with
this class of agents
The BCG also performed a phase III trial (EORTC
10961) to compare the efﬁcacy and tolerability of the
combination of doxorubicin and paclitaxel (AT) with
a standard doxorubicin plus cyclophosphamide (AC)
regimen as ﬁrst-line chemotherapy for metastatic breast
cancer. No differences in PFS, being six months in
both the treatment arms (P=0.65), or OS (20.6 versus
20.5 months; P=0.49) were observed between the two
treatment arms. The AT regimen was accompanied
by a higher incidence of toxicity which compromised
doxorubicin-delivered dose-intensity in this arm. 22 In
a later meta-analysis, which included the results of
this trial, taxane-based combinations were found to be
better than anthracycline-based combinations in terms
of response rates (HR=0.63, 95%CI: 0.54−0.72; P=0.001)
and PFS (HR=0.92, 95%CI: 0.85−0.99; P=0.031) but not in
terms of OS (HR=0.95, 95%CI: 0.88−1.03; P=0.24). 23
6. Pioneering work in clinical-translational trials
During the last decade pioneering work in breast cancer
translational research and biobanking has been led by
BCG in collaboration with other EORTC groups and
other international partners. Based on the current BCG
experience, high-quality clinical trials with a strong
translational research component and/or answering a
molecular biology-based primary question are feasible in
a multicenter and multinational setting in Europe.
The “p53 trial” (EORTC 10994 BIG 1-00), one of the ﬁrst
international trials with a molecular-based question as
primary endpoint, did not conﬁrm its primary hypothesis
that a somatic p53 mutation conferred additional
beneﬁt to taxanes over anthracyclines. However, the
prognostic value of p53 alterations in early breast
cancer was conﬁrmed. Importantly, enrolment in this
trial demanded the availability of a snap-frozen core
biopsy from each patient, making this enterprise one
of the largest neoadjuvant breast cancer trials ever
done with collection of fresh-frozen tumor samples
from all enrolled patients. 24 Using this valuable material
two important translational research projects have been
performed and published in high-proﬁle journals: the
identiﬁcation of molecular apocrine breast tumors by
microarray analysis, and a stroma-related gene signature
which predicts resistance to neoadjuvant chemotherapy
in breast cancer. 25,26
The EORTC 10041 BIG 3-04 MINDACT (Microarray In
Node-negative and one to three positive lymph node
Disease may Avoid ChemoTherapy) is a phase III trial
evaluating the clinical utility and added clinical beneﬁt
of the 70-gene genomic signature (MammaPrint™) to
traditional clinical-pathological methods for selecting
early breast cancer patients for adjuvant chemotherapy.
MINDACT, together with TailorX run in the USA, is the
ﬁrst clinical trial evaluating the clinical utility of a
multigene tool. It is also the ﬁrst trial to collect frozen
tumor samples and run gene expression proﬁling on a
real-time basis (results provided within a maximum of
ten days) and in a multinational, multicenter setting.
The results of the MINDACT pre-planned pilot phase
which included the ﬁrst 800 patients were presented
at the EBCC7 in 2010 and ECCO in 2011. 27,28 The main
conclusions were that this logistically complex trial is
feasible in a multinational multicenter setting, and that
the proportion of discordant patients, the estimated
reduction of chemotherapy prescription by using the
70-gene proﬁle, and the compliance to treatment
assignment in the discordant group were all according
to plan. The trial completed the planned accrual of
6600 patients in July 2011. This landmark trial collected
fresh-frozen tumor samples, parafﬁn tissue blocks and
blood/serum samples from all enrolled patients for
current and future translational research This valuable
annotated high-quality biological material is stored in
an independent biobank and available to the scientiﬁc
community according to a speciﬁc policy (available at
www.breastinternationalgroup.org).
7. Collaboration within intergroup trials
With the identiﬁcation of speciﬁc molecular subtypes
of breast cancer, international collaboration between
different cooperative groups has become indispensible
to achieve further improvements in the management
of breast cancer, especially in the area of systemic
therapy for early breast cancer. Intergroup collaboration
avoids duplication of efforts and wasting of resources
and allows the recruitment of the necessary numbers of
patients of each molecular subtype. The EORTC is one
of the founding organizations of the Breast International
Group (BIG), a worldwide network of 44 breast cancer
research groups from 40 countries, founded in 1996
by Martine Piccart (former EORTC President and BCG
Chair) and Aron Goldhirsch. Over the past 15 years,
BIG has formed a powerful platform for clinical and
translational collaboration and successfully performed
landmark and practice changing trials. The BCG has
actively participated in and coordinated some of these
important international, intergroup studies, enrolling
more than 5500 patients; most important of these studies
are “p53 trial”, MINDACT, HERA, ALTTO, MA17, IES and
SOFT.
The Herceptin Adjuvant (HERA) trial (BIG 0101) was one
of several large trials designed to test the efﬁcacy of
trastuzumab in the adjuvant treatment of women with
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HER-2 over-expressing and/or ampliﬁed operable breast
cancer. The results showed that one year treatment with
adjuvant trastuzumab after completion of chemotherapy
and radiotherapy is associated with signiﬁcant clinical
beneﬁt compared to observation (4-year disease-free
survival [DFS] 78.6% vs. 72.2%). 29 In the same ﬁeld,
the BCG has joined the ALTTO trial (Adjuvant Lapatinib
and/or Trastuzumab Treatment Optimization), which
recruited more than 8000 patients, to test the hypothesis
that combining or sequencing two anti-HER-2 targeted
agents in the adjuvant treatment of patients with HER-2-
positive breast cancer confers additional beneﬁt over one
year of trastuzumab alone.
In addition, the BCG participated in two important
trials of adjuvant endocrine therapy for early breast
cancer. The MA.17 study included 5187 postmenopausal
women to investigate the extended adjuvant therapy
with the aromatase inhibitor letrozole after ﬁve years
of tamoxifen. 30 The results showed that ﬁve years
of letrozole after tamoxifen reduces the risk of late
recurrences, improves DFS and distant disease-free
survival (DDFS) but not OS. The Intergroup Exemestane
Study (IES) enrolled 4742 patients to investigate whether
exemestane,when given to postmenopausal womenwho
remained free of recurrence after receiving adjuvant
tamoxifen therapy for two to three years for primary
breast cancer, could prolong disease DFS, as compared
with continued tamoxifen therapy for a total of ﬁve years.
Exemestane led to a 24% reduction in risk of recurrence
corresponding to an absolute beneﬁt of 3.3% by the end
of treatment (i.e., 2.5 years after randomization). This
strategy also reduced the risk of contralateral breast
cancer, endometrial cancer and other primary cancers.
OS was not signiﬁcantly different between the two
groups. 31,32
8. Future directions
The strategic plan of the BCG for future research includes
three distinct albeit overlapping areas: loco-regional
therapy, (neo-)adjuvant systemic therapy, trials in the
metastatic setting, and niche studies (such asmale breast
cancer). For each of these areas the group has considered
the prevailing EORTC strategy of focusing on practice
changing studies and translational research, with an
emphasis on niche trials. The following are examples of
this work.
8.1. Loco-regional therapy
The EORTC 10981–22023 AMAROS (After Mapping of the
Axilla: Radiotherapy Or Surgery) study is a phase III
trial with the objective to prove equivalent local/regional
control between axillary lymph node dissection (ALND)
and axilla radiotherapy (ART) in sentinel node (SN)
positive early BC patients. The trial achieved the planned
accrual in April 2010. First interim analysis showed a high
identiﬁcation rate of SN (97%), 34% of the SN’s containing
metastases. 33 Further, patterns of care analysis revealed
that the lack of knowledge of the axillary nodal status
in SN positive patients does not inﬂuence the type
or dose of adjuvant chemotherapy. 34 A follow-up trial,
continuing to optimize the loco-regional management of
early breast cancer, is being developed.
Furthermore BCG centers participate in a worldwide
trial to assess the optimal radiation dose and fractiona-
tion schedule for DCIS (EORTC 22085–10083).
8.2. (Neo-)adjuvant systemic therapy studies
The reﬁnement of targeted therapy against HER-2 is
being assessed in the EORTC 10054 trial (Lapatax). This
is a phase I−II trial designed to compare the use of
lapatinib, trastuzumab or lapatinib plus trastuzumab in
combination with docetaxel after FEC as neoadjuvant
chemotherapy for operable and locally advanced breast
cancer. The trial will enroll 150 patients from European
centers and will collect frozen tumor and blood samples
for translational research.
The BCG will continue to explore the neo-adjuvant
setting as a means of speeding up drug development
for speciﬁc molecular subtypes of early breast cancer as-
sociated with important translational research projects.
Due to inherent recruitment challenges, these studies
will most likely be performed within the EORTC Network
of Core Institutions (NOCI) and/or within the recently
created international network neo-BIG.
8.3. Niche studies
Breast cancer in speciﬁc populations such as male,
elderly or very young patients are also areas of great
interest that must be explored by academic groups.
The BCG is currently coordinating a worldwide
collaboration (including BIG and the North American
Breast Cancer Groups [NABCG] networks) aiming to
obtain a better clinical and biological characterization of
male breast cancer (EORTC 10085 BIG2-07 trial). This is an
international joint program with three planned parts:
(a) a retrospective joint analysis of the largest series of
male breast cancer cases in terms of clinical and
biological (centrally accessed) characteristics;
(b) a prospective registry of all male breast cases treated
within this large international network within a
period of two years;
(c) depending on the results of the previous parts, a
prospective randomized clinical trial of adjuvant
endocrine therapy.
It is important to emphasize that all previous efforts
to run randomized trials in this patient population have
failed and that only this large, worldwide collaboration
may render it possible to achieve.
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The BCG will continue to collaborate with the EORTC
Elderly Task Force in its efforts to develop trials of new
therapies/strategies for this ever increasing and quite
speciﬁc patient population.
As in the early setting, breast cancer in the metastatic
setting must also be studied separately according to
different molecular subtypes with foreseeable conse-
quences for patient accrual. A variety of new agents
are already in development, and their number will likely
further increase in the next few years. Only through well
organized international collaboration will advances in
this area be achieved. The BCG will increase its focus
on the metastatic setting and take the lead in several
of these projects.
9. Conclusions
The BCG has been successful in its mission to carry out
large clinical studies covering the entire spectrum of
breast tumors from intraductal carcinoma to metastatic
disease. These studies have focused on optimization of
local and systemic therapy of breast cancer and have
also considered quality of life and health economics.
Over ﬁve decades, the BCG has successfully performed a
series of practice-changing trials and has enrolled several
thousand patients. These studies have contributed to the
clinical knowledge on the treatment of breast cancer and
have inﬂuenced clinical research and clinical practice
worldwide.
In this new era of molecular-based medicine, the BCG
is prioritizing translational research, biobanking, quality
assurance issues, and trials in speciﬁc populations.
Together with the increasing participation of young
oncologists and active lobbying for independent and
centralized European funding resources, these activities
will certainly maintain the status of the BCG as a
world renowned leading player in clinical breast cancer
research.
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